Plaque Psoriasis Clinical Trial
Official title:
Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®. The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.
Status | Recruiting |
Enrollment | 494 |
Est. completion date | December 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent. 2. Male and female patients aged 18-65 years, body weight = 50 kg and = 120 kg. 3. Established clinical diagnosis plaque psoriasis, lasting at least 6 months before the screening. 4. Plaque psoriasis of moderate or severe severity of stable course with: - PASI = 12 points; - BSA = 10 %; - sPGA = 3 points. 5. Patients who have been shown to undergo systemic therapy and/or patients who have had insufficient therapeutic efficacy of at least 1 previous standard systemic therapy for psoriasis, including phototherapy, therapy with cytostatic and immunosuppressive drugs, or who have had intolerance to standard systemic therapy. Exclusion Criteria: 1. Data on intolerance or hypersensitivity to any components of the drugs, or to any other human proteins, immunoglobulin preparations. 2. A history of severe hypersensitivity reactions of any etiology. 3. Other (other than plaque) forms of psoriasis. 4. Drug-induced psoriasis. 5. Data on the use of the Adalimumab or any preparations of monoclonal antibodies inhibiting TNF-a at any time during life. 6. The presence of Adalimumab antibodies. 7. Extensive surgical intervention performed less than 30 days before the screening period, or planned extensive surgical intervention during the study period. 8. Active or latent tuberculosis 9. Lymphoproliferative diseases, lymphoma, leukemia, myeloproliferative diseases or a history of multiple myeloma. 10. Any other malignant neoplasms currently or in anamnesis within the last 5 years, with the exception of completely removed and/or cured. 11. Confirmed coronavirus infection caused by COVID-19 within 8 weeks prior to the screening period. 12. Anamnestic data on the presence of syphilis, viral hepatitis B, viral hepatitis C, HIV. 13. Vaccination with live or attenuated vaccines within 8 weeks before the screening period. 14. Hepatic and/or renal insufficiency. 15. Pregnancy or lactation. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Regional dermatovenerologic dispensary | Barnaul | |
Russian Federation | Chelyabinsk Regional Clinical Dermatovenerologic Dispensary | Chelyabinsk | |
Russian Federation | Interregional Clinical Diagnostic Center | Kazan' | |
Russian Federation | City clinical hospital n.a.Botkin | Moscow | |
Russian Federation | Rheumatology research Instititue n.a.Nasonova | Moscow | |
Russian Federation | State Scientific Center of Dermatovenerology and Cosmetology | Nizhny Novgorod | |
Russian Federation | Reafan | Novosibirsk | |
Russian Federation | New Clinic | Pyatigorsk | |
Russian Federation | Dermatovenerologic dispensary N10 | Saint Petersburg |
Lead Sponsor | Collaborator |
---|---|
Mabscale, LLC |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of patients who achieved a response according to the PASI criterion of 75 (a decrease in the severity and prevalence of psoriasis by =75% from the baseline level assessed by the PASI index) | after 16 weeks of therapy (assessment at Visit 10) | ||
Primary | Proportion of patients with positive antibody titer to Adalimumab | 51 weeks of therapy | ||
Primary | Percentage of patients who have neutralizing antibodies to Adalimumab | 51 weeks of therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01194219 -
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
Recruiting |
NCT06030076 -
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
|
||
Completed |
NCT04263610 -
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
|
Phase 4 | |
Completed |
NCT02601469 -
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05600036 -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Not yet recruiting |
NCT05036889 -
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
|
N/A | |
Completed |
NCT04603027 -
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03638258 -
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT02881346 -
Efficacy and Tolerability of Enstilar® in Daily Practice
|
||
Recruiting |
NCT02611349 -
Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT02251678 -
Evaluate the Effect of Elimune Capsules
|
Phase 1 | |
Completed |
NCT01987843 -
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Terminated |
NCT01708629 -
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
|
Phase 3 | |
Completed |
NCT01230138 -
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Withdrawn |
NCT00747032 -
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
Suspended |
NCT01228656 -
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
|
Phase 2 | |
Completed |
NCT00540618 -
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
|
Phase 2 |